David Cella1, Elizabeth A Hahn, Kelly Dineen. 1. Evanston Northwestern Healthcare and Northwestern University, Evanston, Illinois 60201, USA. d-cella@nwu.edu
Abstract
INTRODUCTION: There has been increased recent attention to the clinical meaningfulness of group change scores on health-related quality of life (HRQL) questionnaires. It has been assumed that improvements and declines of comparable magnitude have the same meaning or value. METHOD: We assessed 308 cancer patients with the Functional Assessment of Cancer Therapy (FACT) and a Global Rating of Change. Patients were classified into five levels of change in HRQL and its dimensions based upon their responses to retrospective ratings of change after 2 months: sizably worse, minimally worse, no change, minimally better, and sizably better. Raw score and standardized score changes on the FACT-G subscales and total score were then compared across different categories of patient-rated change. RESULTS: The relationship between actual FACT change scores and retrospective ratings of change was modest but usually statistically significant (r: 0.07 to 0.35). Change scores associated with each retrospective rating category were evaluated to determine estimates of meaningful difference. Patients who reported global worsening of HRQL dimensions had considerably larger change scores than those reporting comparable global improvements. Although related to a ceiling effect, this remained true even after removing cases that began near the ceiling of the questionnaire. DISCUSSION: Relatively small gains in HRQL have significant value. Comparable declines may be less meaningful, perhaps due to patients' tendency to minimize personal negative evaluations about one's condition. This has important implications for the interpretation of the meaningfulness of change scores in HRQL questionnaires. Factors such as adaptation to disease, response shift, dispositional optimism and the need for signs of clinical improvement may be contributing to the results and should be investigated in future studies.
INTRODUCTION: There has been increased recent attention to the clinical meaningfulness of group change scores on health-related quality of life (HRQL) questionnaires. It has been assumed that improvements and declines of comparable magnitude have the same meaning or value. METHOD: We assessed 308 cancerpatients with the Functional Assessment of Cancer Therapy (FACT) and a Global Rating of Change. Patients were classified into five levels of change in HRQL and its dimensions based upon their responses to retrospective ratings of change after 2 months: sizably worse, minimally worse, no change, minimally better, and sizably better. Raw score and standardized score changes on the FACT-G subscales and total score were then compared across different categories of patient-rated change. RESULTS: The relationship between actual FACT change scores and retrospective ratings of change was modest but usually statistically significant (r: 0.07 to 0.35). Change scores associated with each retrospective rating category were evaluated to determine estimates of meaningful difference. Patients who reported global worsening of HRQL dimensions had considerably larger change scores than those reporting comparable global improvements. Although related to a ceiling effect, this remained true even after removing cases that began near the ceiling of the questionnaire. DISCUSSION: Relatively small gains in HRQL have significant value. Comparable declines may be less meaningful, perhaps due to patients' tendency to minimize personal negative evaluations about one's condition. This has important implications for the interpretation of the meaningfulness of change scores in HRQL questionnaires. Factors such as adaptation to disease, response shift, dispositional optimism and the need for signs of clinical improvement may be contributing to the results and should be investigated in future studies.
Authors: M J Brady; D F Cella; F Mo; A E Bonomi; D S Tulsky; S R Lloyd; S Deasy; M Cobleigh; G Shiomoto Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: Vikki Ho; Romain Pasquet; Shaman Luo; Gang Chen; Paul Goss; Dongsheng Tu; Philip Lazarus; Harriet Richardson Journal: Breast Cancer Res Treat Date: 2020-08-01 Impact factor: 4.872
Authors: Carolyn E Schwartz; Rita Bode; Nicholas Repucci; Janine Becker; Mirjam A G Sprangers; Peter M Fayers Journal: Qual Life Res Date: 2006-09-26 Impact factor: 4.147
Authors: Erin Wong; Liying Zhang; Marc Kerba; Palmira Foro Arnalot; Brita Danielson; May Tsao; Gillian Bedard; Nemica Thavarajah; Paul Cheon; Cyril Danjoux; Natalie Pulenzas; Edward Chow Journal: Support Care Cancer Date: 2015-02-10 Impact factor: 3.603
Authors: Kathleen D Lyons; Jay G Hull; Peter A Kaufman; Zhongze Li; Janette L Seville; Tim A Ahles; Alice B Kornblith; Mark T Hegel Journal: J Psychosoc Oncol Date: 2015-02-10
Authors: Susan E Yount; Nan Rothrock; Michael Bass; Jennifer L Beaumont; Deborah Pach; Thomas Lad; Jyoti Patel; Maria Corona; Rebecca Weiland; Katherine Del Ciello; David Cella Journal: J Pain Symptom Manage Date: 2013-11-07 Impact factor: 3.612
Authors: C Krishnan Nair; P S George; K S Rethnamma; R Bhargavan; S Abdul Rahman; A P Mathew; M Muralee; K Cherian; P Augustine; M I Ahamed Journal: Indian J Surg Oncol Date: 2014-10-16
Authors: Roxanne E Jensen; Carol M Moinpour; Arnold L Potosky; Tania Lobo; Elizabeth A Hahn; Ron D Hays; David Cella; Ashley Wilder Smith; Xiao-Cheng Wu; Theresa H M Keegan; Lisa E Paddock; Antoinette M Stroup; David T Eton Journal: Cancer Date: 2016-10-03 Impact factor: 6.860